- Home
- PTHL vs NERV Comparison
PTHL vs NERV Comparison
Compare PTHL & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- NERV
- Stock Information
- Founded
- PTHL 1998
- NERV 2007
- Country
- PTHL China
- NERV United States
- Employees
- PTHL N/A
- NERV N/A
- Industry
- PTHL
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- NERV Health Care
- Exchange
- PTHL Nasdaq
- NERV Nasdaq
- Market Cap
- PTHL 13.5M
- NERV 12.0M
- IPO Year
- PTHL 2024
- NERV 2014
- Fundamental
- Price
- PTHL $0.91
- NERV $2.25
- Analyst Decision
- PTHL
- NERV Hold
- Analyst Count
- PTHL 0
- NERV 1
- Target Price
- PTHL N/A
- NERV $5.00
- AVG Volume (30 Days)
- PTHL 1.8M
- NERV 21.0K
- Earning Date
- PTHL 01-01-0001
- NERV 11-04-2025
- Dividend Yield
- PTHL N/A
- NERV N/A
- EPS Growth
- PTHL N/A
- NERV N/A
- EPS
- PTHL N/A
- NERV 1.48
- Revenue
- PTHL $448,196.00
- NERV N/A
- Revenue This Year
- PTHL N/A
- NERV N/A
- Revenue Next Year
- PTHL N/A
- NERV N/A
- P/E Ratio
- PTHL N/A
- NERV $1.47
- Revenue Growth
- PTHL N/A
- NERV N/A
- 52 Week Low
- PTHL $0.51
- NERV $1.15
- 52 Week High
- PTHL $32.00
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- PTHL 30.66
- NERV 54.15
- Support Level
- PTHL $0.82
- NERV $2.26
- Resistance Level
- PTHL $0.98
- NERV $2.19
- Average True Range (ATR)
- PTHL 0.17
- NERV 0.12
- MACD
- PTHL 0.53
- NERV -0.03
- Stochastic Oscillator
- PTHL 55.65
- NERV 45.65
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.